.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BD03_LansoprazoleAmoxicillinA.LansoprazoleAmoxicillinA .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BD03_LansoprazoleAmoxicillinA.LansoprazoleAmoxicillinA| name: | LansoprazoleAmoxicillinAndMetronidazole | |
| ATC code: | A02BD03 | route: | oral |
| compartments: | 1 | |
| dosage: | 30 | mg |
| volume of distribution: | 15 | L |
| clearance: | 1.2 | L/hr |
| other parameters in model implementation | ||
This is a triple therapy combination used primarily for the eradication of Helicobacter pylori infection, commonly causing gastric and duodenal ulcers. Lansoprazole is a proton pump inhibitor, amoxicillin is a broad-spectrum penicillin antibiotic, and metronidazole is a nitroimidazole antimicrobial. This combination is approved and widely used globally as a standard first-line treatment for H. pylori infection.
Pharmacokinetic parameters estimated for healthy adult population, as no direct publication reporting the PK parameters for the fixed-dose combination with ATC code A02BD03 was retrieved. Estimates are based on published PK data for each individual drug given orally in the context of triple therapy.